Background The beneficial effects of radioactive iodine (RAI) ablation for intermediate-risk
papillary thyroid cancer (PTC) patients are still controversial. Materials and methods To …

The use of radioactive iodine (RAI) ablation in patients with intermediate-risk papillary
thyroid carcinoma (PTC) who show microscopic extrathyroidal extension (ETE), regional …

Objective The utility of radioiodine (RAI) therapy in intermediate‐risk papillary thyroid
carcinoma (PTC) remains a topic of ongoing discussion. This systematic review and meta …

It remains controversial whether papillary thyroid cancer (PTC) patients with low-to
intermediate-risk disease should receive radioactive iodine (RAI) after total thyroidectomy …

Context Current guidelines recommend a selective use of radioiodine treatment (RAI) for
papillary thyroid cancer (PTC). Objective This work aimed to determine how policy changes …

Background Papillary thyroid cancer (PTC) is a common endocrine malignancy with
relatively good prognosis. Radioactive iodine (RAI) is considered effective for patients with …

Objective: Postthyroidectomy radioiodine (RAI) therapy is indicated for papillary thyroid
carcinoma (PTC) with high-risk features. There is variability in the timing of RAI therapy with …

Background The clinical outcomes of delayed radioiodine remnant ablation (RRA) therapy
in patients with low-risk papillary thyroid carcinoma (PTC) are unclear. We aimed to evaluate …

Background The aim of this study was to use current American Thyroid Association (ATA)
management guidelines to identify groups who might be at risk of overtreatment with …

Context: Papillary thyroid cancer (PTC) is the most common endocrine malignancy. The long-
term prognosis is generally excellent. Due to a paucity of data, debate exists regarding the …